New PET tracer aims to spot prostate cancer more clearly
NCT ID NCT03995888
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a new radioactive imaging agent called rhPSMA-7.3 (18F) in 24 people: some healthy volunteers and some with prostate cancer. The goal was to check safety and see how the agent spreads in the body and how well it lights up cancer on PET scans. The study is complete, but results are not yet reported.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rhPSMA-7.3 (18F) injection
What this could lead to
If successful, this could lead to a more accurate PET scan to detect prostate cancer, helping doctors see where the cancer is in the body.
What could go wrong
This is an early phase 1 study with only 24 people, so it is too small to prove the scan works better than current methods. The main goal is safety, not yet effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Research Services Turku - CRST Oy
Turku, FI-20520, Finland